Share on StockTwits

Spectrum Pharmaceuticals (NASDAQ:SPPI) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued on Thursday. They currently have a $8.60 price objective on the stock. Zacks‘s price target points to a potential upside of 9.69% from the company’s current price.

Separately, analysts at TheStreet downgraded shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $11.72.

Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up 1.79% on Thursday, hitting $7.98. The stock had a trading volume of 365,890 shares. Spectrum Pharmaceuticals has a 52 week low of $6.36 and a 52 week high of $10.32. The stock has a 50-day moving average of $7.29 and a 200-day moving average of $8.22. The company’s market cap is $506.3 million.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its earnings results on Thursday, May 8th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.23. The company had revenue of $40.10 million for the quarter, compared to the consensus estimate of $39.49 million. During the same quarter in the prior year, the company posted $0.01 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts predict that Spectrum Pharmaceuticals will post $-0.70 earnings per share for the current fiscal year.

Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.